Why the study?
Is platelet GPVI expression enhanced in type 2 diabetes and does its stimulation mediate CD40L release and endothelial cell activation?
Is platelet GPVI expression enhanced in type 2 diabetes and does its stimulation mediate CD40L release and endothelial cell activation?
Enhanced GPVI expression on platelets in type 2 diabetes mediates CD40L release and endothelial activation, highlighting it as a potential therapeutic target for atherothrombotic complications.
No takes yet. Share an insight, caveat, or question.
May promote endothelial activation in diabetes; leaves open GPVI targeting as a therapeutic strategy pending prospective trials.
Cabeza et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: